DeCure's autonomous Cancer AI scientist is researching a drug-repurposing hypothesis for myeloid neoplasm — screening already-approved drugs against its 47-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleMyeloid neoplasm maps to a 47-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for myeloid neoplasm is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
Cbl proto-oncogene B (CBLB) — CBLB is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-methyl-1,2,4-triazol-3-yldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8QTG · 1.419 Å · ligand 3-[3-[3-methyl-1-(4-methyl-1,2,4-triazol-3-yl)cyclobutyl]phenyl]-5-(trifluoromethyl)-1~{H}-pyridin-2-one (WUQ). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Clinical Cancer Research · 2024 · 0 citations · open access
CHIPing Away at Proteomics to Find Correlations with Myeloid Neoplasms
AbstractPlasma proteomic profiling to identify associations with myeloid neoplasm (MN) risk highlights the potential of integrating proteins and genetic biomarkers for the detection of individuals at high risk of developing MN. These proteins also offer valuable insights into biological pathways and inflammatory mechanisms involved in the progression of clonal hematopoiesis to MN. See related article by Tran et al., p. 3220.
Medical Journal of Dr D Y Patil Vidyapeeth · 2025 · 0 citations · open access
Clinico-hematological and Cytogenetic Study of Myeloid Neoplasms: A cross-sectional Study from South India
AbstractA BSTRACT Background: Myeloid neoplasms are clonal diseases arising in hematopoietic stem or progenitor cells consisting of myeloproliferative neoplasm (MPN), myelodysplastic syndrome (MDS), and acute myeloid leukemia (AML). Aim: To re-classify the myeloid neoplasm as per the World Health Organization (WHO)-5 classification and to study the frequency of occurrence and clinical, hematological, and cytogenetic profile of myeloid neoplasms. Settings and Design: A cross-sectional study was conducted for a period of 1 and a 1/2 years from January 2019 to June 2020. Materials and Methods: All the cases newly diagnosed as myeloid neoplasms during this period were included in the study. Clinical features, and hematological and cytogenetic findings were compiled. Statistical Analysis: For categorical data, the number and percentage were used. The Chi-square (χ2) test was used for association between two categorical variables. If the P value was < 0.05, then the results were considered to be statistically significant. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) software v. 23 (IBM Statistics, Chicago, USA) and Microsoft Office 2007. Results and Conclusion: A total of 51 cases were observed during the study period. The cases ranged from 14 to 74 years with maximum cases occurring between 51 and 60 years with a male-to-female (M: F) ratio of 1:1.25. Among the 51 cases of myeloid neoplasms, 28 (55%) cases of MPN, 14 (27%) cases of AML, five (10%) cases of MDS, and four (8%) cases of MPN/MDS were observed in their decreasing frequency. The most common symptoms were constitutional symptoms, such as generalized weakness, easy fatigability, and fever. Bone marrow study played a major role in diagnosis. The cytogenetic study complemented the diagnosis. A high clinical suspicion along with a good morphological diagnosis using peripheral smear, bone marrow aspiration, and biopsy supplemented by special stains and molecular studies will enable early and efficient diagnosis of myeloid neoplasms.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
